| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.01 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |